Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients
Autore:
Becouarn, Y; Gamelin, E; Coudert, B; Negrier, S; Pierga, JY; Raoul, JL; Provencal, J; Rixe, O; Krisch, C; Germa, C; Bekradda, M; Mignard, D; Mousseau, M;
Indirizzi:
Inst Bergonie, Reg Canc Ctr, Dept Digest Oncol, F-33076 Bordeaux, France Inst Bergonie Bordeaux France F-33076 st Oncol, F-33076 Bordeaux, France Ctr Paul Papin, Angers, France Ctr Paul Papin Angers FranceCtr Paul Papin, Angers, France Ctr Georges Francois Leclerc, Dijon, France Ctr Georges Francois Leclerc Dijon France ancois Leclerc, Dijon, France Ctr Leon Berard, F-69373 Lyon, France Ctr Leon Berard Lyon France F-69373 tr Leon Berard, F-69373 Lyon, France Inst Curie, Paris, France Inst Curie Paris FranceInst Curie, Paris, France Aventis, Paris, France Aventis Paris FranceAventis, Paris, France Ctr Eugene Marquis, Rennes, France Ctr Eugene Marquis Rennes FranceCtr Eugene Marquis, Rennes, France CHU Grenoble, F-38043 Grenoble, France CHU Grenoble Grenoble France F-38043 Grenoble, F-38043 Grenoble, France Clin C Bernard, Metz, France Clin C Bernard Metz FranceClin C Bernard, Metz, France Ctr Hosp Univ, Amiens, France Ctr Hosp Univ Amiens FranceCtr Hosp Univ, Amiens, France Cvitkovic & Associes Consultants, Le Kremlin Bicetre, France Cvitkovic & Associes Consultants Le Kremlin Bicetre France etre, France
Titolo Testata:
JOURNAL OF CLINICAL ONCOLOGY
fascicolo: 22, volume: 19, anno: 2001,
pagine: 4195 - 4201
SICI:
0732-183X(20011115)19:22<4195:RMPISC>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
HIGH-DOSE LEUCOVORIN; PLUS SUPPORTIVE CARE; FIRST-LINE TREATMENT; CONTINUOUS-INFUSION; 5-FLUOROURACIL REGIMEN; TRIAL; CHEMOTHERAPY; CPT-11; RESISTANT; BOLUS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
43
Recensione:
Indirizzi per estratti:
Indirizzo: Becouarn, Y Inst Bergonie, Reg Canc Ctr, Dept Digest Oncol, 229 Cours Argonne, F-33076Bordeaux, France Inst Bergonie 229 Cours Argonne Bordeaux France F-33076 rance
Citazione:
Y. Becouarn et al., "Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients", J CL ONCOL, 19(22), 2001, pp. 4195-4201

Abstract

Purpose : To assess antitumor activity and safety of two regimens in advanced colorectal cancer (CRC) patients with proven fluorouracil (5-FU) resistance in a randomized phase II study: 5-FU/folinic acid (FA) combined with alternating irinotecan (also called CPT-11) and oxaliplatin (FC/FO tritherapy), and an oxaliplatin/irinotecan (OC) combination. Patients and Methods: Sixty-two patients were treated: arm FC/FO (32 patients) received, every 4 weeks, FA 200 mg/m(2) followed by a 400-mg/m(2) 5-FUbolus injection, then a 600-mg/m(2) continuous infusion of 5-FU on days 1 and 2 every 2 weeks administered alternately with irinotecan (180 mg/m(2) on day 1) and oxaliplatin (85 mg/m(2) on day 15). Arm OC (30 patients) received oxaliplatin 85 Mg/M2 and irinotecan 200 mg/m(2) every 3 weeks. Results: In an intent-to-treat analysis, two partial responses lasting 10.7 and 16 months were observed with the tritherapy regimen, and seven (median duration, 11 months; range, 10.6 to 11.4 months) were observed with the bitherapy regimen. Median progression-free and overall survival times were 8.2 and 9.8 months, respectively, in the FC/FO arm and 8.5 and 12.3 months, respectively, in the OC arm. Main grade 3/4 toxicities were, respectively, neutropenia, 53% and 47%; febrile neutropenia, 13% and 3%; diarrhea, 19% and 10%; vomiting, 6% and 13%; and neurosensory toxicity, 3% and 3%. No treatment-related deaths occurred. Conclusion: The every-3-weeks OC combination is safe and active in advanced 5-FU-resistant CRC patients. The lower activity data seen with the tritherapy regimen may be related to the lower dose intensities of irinotecan andoxaliplatin in this schedule. (C) 2001 by American Society of Clinical Oncology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 22:00:50